Michael B Fisher

Summary

Publications

  1. ncbi request reprint The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
  2. ncbi request reprint Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin
    Michael B Fisher
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:270-5. 2002
  3. ncbi request reprint Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance
    Michael B Fisher
    Discovery Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc, Eastern Point Rd, Groton, Connecticut 06340, USA
    Drug Metab Dispos 30:1087-93. 2002
  4. ncbi request reprint A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
  5. ncbi request reprint The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
  6. ncbi request reprint In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
  7. ncbi request reprint Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008

Collaborators

  • Timothy J Carlson
  • Timothy J Strelevitz
  • Sara M Skaggs
  • Robert S Foti

Detail Information

Publications7

  1. ncbi request reprint The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective
    Michael B Fisher
    Cara Therapeutics, Tarrytown, NY 10591, USA
    Curr Drug Metab 8:694-9. 2007
    ..The opportunity exists to increase the examination of intestinal metabolism of drugs and drug candidates in industry...
  2. ncbi request reprint Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin
    Michael B Fisher
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug Metab Dispos 30:270-5. 2002
    ..Viewed collectively, these results illustrate the utility of alamethicin in the examination of coupled oxidative-conjugative metabolism and the synergy of LC-NMR and LC-MS in metabolite identification...
  3. ncbi request reprint Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance
    Michael B Fisher
    Discovery Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Pfizer Inc, Eastern Point Rd, Groton, Connecticut 06340, USA
    Drug Metab Dispos 30:1087-93. 2002
    ..Benzydamine N-oxidation in liver microsomes from all common preclinical species demonstrated heat sensitivity. This information should be considered when extrapolating metabolism data of xenobiotics from these in vitro systems...
  4. ncbi request reprint A streamlined method to predict hepatic clearance using human liver microsomes in the presence of human plasma
    Sara M Skaggs
    Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism Pfizer, Inc Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 53:284-90. 2006
    ..This can be time consuming for multiple compounds since it requires separate experiments to determine in vitro lability, and free fraction...
  5. ncbi request reprint The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism
    Michael B Fisher
    Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
    Curr Opin Drug Discov Devel 9:101-9. 2006
    ..The concepts and evidence behind this phenomenon as it relates to complexities in blocking metabolic clearance are presented herein...
  6. ncbi request reprint In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance
    Timothy J Strelevitz
    Pfizer Inc, PGRD, Pharmacokinetics, Dynamics, and Metabolism, Eastern Point Road, Groton, CT 06340, USA
    J Pharm Sci 95:1334-41. 2006
    ..This method should have utility in drug discovery for the identification of factors limiting oral bioavailability...
  7. ncbi request reprint Recent advances in high throughput screening for ADME properties
    Timothy J Carlson
    Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
    Comb Chem High Throughput Screen 11:258-64. 2008
    ..Future advances will further improve the ability to make decisions on molecules earlier in drug discovery...